Assembly Biosciences Appoints New CEO, CMO, CFO

Ticker: ASMB · Form: 8-K · Filed: Mar 15, 2024 · CIK: 1426800

Assembly Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyAssembly Biosciences, INC. (ASMB)
Form Type8-K
Filed DateMar 15, 2024
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: management-change, executive-appointment

TL;DR

New CEO, CMO, and CFO in at Assembly Bio. Big changes ahead?

AI Summary

Assembly Biosciences, Inc. announced on March 12, 2024, a series of significant leadership changes. Dr. Henry "Hank" Alfred, Jr. has been appointed as the new Chief Executive Officer and a member of the Board of Directors. Additionally, Dr. David J. E. Duffield has joined as Chief Medical Officer, and Ms. Jennifer L. Jones has been appointed as Chief Financial Officer. These appointments are effective immediately.

Why It Matters

The appointment of new executive leadership, including a CEO, CMO, and CFO, often signals a strategic shift or a new direction for the company, potentially impacting its future development and financial performance.

Risk Assessment

Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding the company's future strategy and operational execution.

Key Players & Entities

FAQ

Who has been appointed as the new CEO of Assembly Biosciences, Inc.?

Dr. Henry "Hank" Alfred, Jr. has been appointed as the new Chief Executive Officer.

When were these executive appointments effective?

The appointments were effective as of March 12, 2024.

What other key executive positions were filled?

Dr. David J. E. Duffield was appointed as Chief Medical Officer, and Ms. Jennifer L. Jones was appointed as Chief Financial Officer.

Is the new CEO also joining the Board of Directors?

Yes, Dr. Henry "Hank" Alfred, Jr. has been appointed as a member of the Board of Directors.

What is the principal executive office address for Assembly Biosciences, Inc.?

The address is Two Tower Place, 7th Floor, South San Francisco, California 94080.

Filing Stats: 1,088 words · 4 min read · ~4 pages · Grade level 13.4 · Accepted 2024-03-15 16:05:13

Key Financial Figures

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1 Assembly Biosciences, Inc. 2024 Corporate Bonus Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: March 15, 2024 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing